Evidence map›Paper›PMID 33820567›Full record

ArticleWorld journal of surgical oncology2021

Actual survival after resection of primary colorectal cancer: results from a prospective multicenter study.

Inge van den Berg, Robert R J Coebergh van den Braak, Jeroen L A van Vugt, Jan N M Ijzermans, Stefan Buettner

Erratum issuedOpen access · goldAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 56 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 5 pooled it
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 5 syntheses or guidelines pooled it, 88 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Inge van den BergDepartment of Surgery, Erasmus MC - University Medical Center Rotterdam, Rotterdam, 3015 GD, The Netherlands. i.vandenBerg@erasmusmc.nl.ORCID http://orcid.org/0000-0002-7529-4686
Robert R J Coebergh van den BraakDepartment of Surgery, Erasmus MC - University Medical Center Rotterdam, Rotterdam, 3015 GD, The Netherlands.
Jeroen L A van VugtDepartment of Surgery, Erasmus MC - University Medical Center Rotterdam, Rotterdam, 3015 GD, The Netherlands.
Jan N M IjzermansDepartment of Surgery, Erasmus MC - University Medical Center Rotterdam, Rotterdam, 3015 GD, The Netherlands.
Stefan BuettnerDepartment of Surgery, Erasmus MC - University Medical Center Rotterdam, Rotterdam, 3015 GD, The Netherlands.
Erasmus MC · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer is the third most common type of cancer in the world. We characterize a cohort of patients who survived up to 5 years without recurrence and identify factors predicting the probability of cure.

methodsWe analyzed data of patients who underwent curative intent surgery for stage I-III CRC between 2007 and 2012 and who had had been included in a large multicenter study in the Netherlands. Cure was defined as 5-year survival without recurrence. Survival data were retrieved from a national registry.

resultsAnalysis of data of 754 patients revealed a cure rate of 65% (n = 490). Patients with stage I disease and T1- and N0-tumor had the highest probability of cure (94%, 95% and 90%, respectively). Those with a T4-tumor or N2-tumor had the lowest probability of cure (62% and 50%, respectively). A peak in the mortality rate for older patients early in follow-up suggests early excess mortality as an explanation. A similar trend was observed for stage III disease, poor tumor grade, postoperative complications, sarcopenia, and R1 resections. Patients with stage III disease, poor tumor grade, postoperative complications, sarcopenia, and R1 resections show a similar trend for decrease in CSS deaths over time.

conclusionIn the studied cohort, the probability of cure for patients with stage I-III CRC ranged from 50 to 95%. Even though most patients will be cured from CRC with standard therapy, standard therapy is insufficient for those with poor prognostic factors, such as high T- and N-stage and poor differentiation grade.

Indexed as

Colonic NeoplasmsColorectal NeoplasmsHumansNeoplasm Recurrence, LocalNeoplasm StagingPrognosisProspective StudiesRetrospective Studies

Identifiers

PMID33820567
PMCPMC8022415
OpenAlexW3139640012

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.